Health Economics›Breast cancer›Advanced or metastatic disease subsequent lines of therapy

Advanced or metastatic disease subsequent lines of therapy

Breast cancer · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 8 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Eribulin monotherapy Variant #01	BRCA	R 22 427	21d	4.1 mo	13.1 mo	2	R 44 854 PFS proxy	21
Olaparib monotherapy Variant #01	BRCA	R 19 741	28d	7.0 mo	19.3 mo	2	R 39 483 PFS proxy	2
Docetaxel monotherapy Variant #02	BRCA	R 2 921	28d	4.7 mo	11.4 mo	9	R 26 293 PFS proxy	5
Gemcitabine monotherapy Variant #01	BRCA	R 1 672	21d	4.6 mo	11.2 mo	7	R 11 705 PFS proxy	15
Capecitabine monotherapy Variant #01	BRCA	R 1 039	21d	4.5 mo	15.6 mo	35	R 36 351 PFS proxy	33
Carboplatin and Paclitaxel (CP) Variant #02	BRCA	R 1 025	21d	12.6 mo	28.2 mo	18	R 18 445 PFS proxy	2
Carboplatin monotherapy Variant #01	BRCA	R 535	21d	~5.8 mo	~21.0 mo	~2	~R 1 070 PFS proxy · indirect	7
Vinorelbine monotherapy Variant #01	BRCA	R 458	21d	4.0 mo	10.8 mo	12	R 5 490 PFS proxy	17
Talazoparib monotherapy Variant #01 Partial	BRCA	—	28d	8.6 mo	19.3 mo	2	—	2

9 of 9 regimens shown